ADAR1 Capital Management LLC 13D and 13G filings for Inhibikase Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 8:13 pm Purchase | 2026-03-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | ADAR1 Capital Management LLC | 13,860,028 9.900% | 1,167,641 (+9.20%) | Filing |
| 2026-02-17 6:22 pm Purchase | 2025-12-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | ADAR1 Capital Management LLC | 12,692,387 9.900% | 4,954,693 (+64.03%) | Filing |
| 2025-08-14 8:27 pm Purchase | 2025-06-30 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | ADAR1 Capital Management LLC | 7,737,694 9.900% | 743,448 (+10.63%) | Filing |
| 2025-02-14 9:04 pm Purchase | 2024-12-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | ADAR1 Capital Management LLC | 6,994,246 9.990% | 6,994,246 (New Position) | Filing |